Drug Trial Radar · NCT00963599
Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)
Last checked: Nov 19, 2026Latest source record: Feb 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
907
Actual
Start
Sep 1999
Primary completion
Nov 1999
Study completion Nov 1999
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Aug 21, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the ability of oral montelukast/loratadine to improve the signs and symptoms of seasonal allergic rhinitis compared with loratadine alone, montelukast alone and placebo.
Conditions
- Seasonal Allergic Rhinitis
Interventions
Comparator: montelukast/loratadineDrug
montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
Comparator: montelukastDrug
montelukast 10 mg tablet taken once daily at bed time for 2 weeks
Comparator: loratadineDrug
loratadine 10 mg tablet taken once daily at bed time for 2 weeks
Comparator: placeboDrug
placebo tablet taken once daily at bed time for 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Daytime Nasal Symptoms ScoreTime frame: Baseline and Week 2
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.